American Association for Cancer Research

SHERPA: Unknown

People

  1. Dang
    Dang
  2. Hudis
    Hudis
  3. Dickler
    Dickler
  4. Steingart
    Steingart
  5. Patil
    Patil
  6. Sugarman
    Sugarman
  7. Modi
    Modi
  8. Norton
    Norton
  9. Traina
    Traina
  10. D'Andrea-Carlino
    D'Andrea-Carlino

Groups

  1. Cardiology (12)
  2. Department of Medicine (12)
  3. Division of Subspecialty Medicine (12)
  4. Breast Medicine Service (11)
  5. Solid Tumor Oncology Division (11)
  6. Survivorship Research (11)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  8. Population Sciences Research Program (8)
  9. Biostatistics Service (7)
  10. Epidemiology and Biostatistics (7)
Search Within
  1. "Cardiology"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (3)
Groups
  1. Cardiology (12)
  2. Department of Medicine (12)
  3. Division of Subspecialty Medicine (12)
  4. Breast Medicine Service (11)
  5. Solid Tumor Oncology Division (11)
  6. Survivorship Research (11)

More Groups

People
  1. Chau Dang (11)
  2. Clifford Hudis (11)
  3. Larry Norton (7)
  4. Maura Dickler (7)
  5. Richard Steingart (7)
  6. Steven Sugarman (6)

More People

Years
  1. 2016 (2)
  2. 2015 (1)
  3. 2013 (1)
  4. 2012 (1)
  5. 2011 (2)
  6. 2010 (1)

More Years

Publications
  1. Cancer Research (9)
  2. Clinical Cancer Research (3)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Meeting Abstract

    Mukku, R. B.; Verma, S.; Liu, J.; Steingart, R.; Hudis, C.; Yu, A. F.; Dang, C.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Trastuzumab interruption for treatment-induced cardiotoxicity in HER2 positive early breast cancer
    Meeting Abstract

    Yu, A. F.; Yadav, N. U.; Lung, B. Y.; Eaton, A. A.; Thaler, H. T.; Hudis, C. A.; Dang, C. T.; Steingart, R. M.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Journal Article

    Morris, P. G.; Chen, C.; Steingart, R.; Fleisher, M.; Lin, N.; Moy, B.; Come, S.; Sugarman, S.; Abbruzzi, A.; Lehman, R.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Symptomatic congestive heart failure after neo/adjuvant dose-dense epirubicin: A retrospective analysis of two trials with long-term follow-up
    Meeting Abstract

    Gajria, D.; Pokuri, V.; Steingart, R.; Hudis, C.; Dang, C.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: No evidence of short-term changes in left ventricular ejection fraction
    Meeting Abstract

    Morris, P. G.; Dickler, M.; Mcarthur, H.; Traina, T.; Godfrey, L.; Steingart, R.; Rugo, H.; Lin, N.; Moy, B.; Come, S.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer
    Meeting Abstract

    Mcarthur, H.; Rugo, H.; Nulsen, B.; Traina, T.; Patil, S.; Zhou, Q.; Steingart, R.; Dang, C.; Park, J.; Moasser, M.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: